| human | Q5 |
| P214 | VIAF ID | 9153470891945082370 |
| P735 | given name | Michael | Q4927524 |
| Michael | Q4927524 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q64053030 | A Workshop on Measuring the Progression of Atrophy Secondary to Stargardt Disease in the ProgStar Studies: Findings and Lessons Learned |
| Q33359510 | A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features |
| Q84558890 | A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein |
| Q24646760 | A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal [...] |
| Q94468688 | A semi-automated machine-learning based workflow for ellipsoid zone analysis in eyes with macular edema: SCORE2 pilot study |
| Q43850892 | Anatomical outcomes of surgery for idiopathic macular hole as determined by optical coherence tomography |
| Q37301735 | Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology |
| Q34392184 | Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology |
| Q104796480 | Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents : SCORE2 report 12: secondary analysis of the SCORE2 clinical trial |
| Q34543206 | Attenuation of choroidal neovascularization by β(2)-adrenoreceptor antagonism |
| Q73977544 | Author's reply |
| Q38376975 | Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4. |
| Q33711660 | Baseline Predictors of Visual Acuity and Retinal Thickness Outcomes in Patients with Retinal Vein Occlusion: Standard Care versus COrticosteroid for REtinal Vein Occlusion Study Report 10 |
| Q38459932 | Baseline characteristics and response to treatment of participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the standard care vs corticosteroid for retinal vein occlusion (SCORE) study: SCORE study report 14 |
| Q64115303 | Choriocapillaris flow impairment surrounding geographic atrophy correlates with disease progression |
| Q91068395 | Choriocapillaris impairment around the atrophic lesions in patients with geographic atrophy: a swept-source optical coherence tomography angiography study |
| Q92930027 | Classification of Regions of Nonperfusion on Ultra-widefield Fluorescein Angiography in Patients with Diabetic Macular Edema |
| Q103013566 | Clinical characteristics and visual outcomes of non-resolving subretinal fluid in neovascular AMD despite continuous monthly anti-VEGF injections: a long-term follow-up |
| Q52687443 | Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial. |
| Q46577000 | Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema |
| Q35971036 | Diabetic macular edema: a review of past, present, and future therapies |
| Q34185374 | Diabetic macular edema: therapeutic options |
| Q92371506 | Diagnostic and Therapeutic Challenges |
| Q84370676 | Diagnostic and therapeutic challenges |
| Q74610977 | Differentiation of degenerative retinoschisis from retinal detachment using optical coherence tomography |
| Q85948220 | Diffuse macular edema in niacin-induced maculopathy may resolve with dosage decrease |
| Q46367910 | Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study |
| Q91947921 | Distribution of Nonperfusion and Neovascularization on Ultrawide-Field Fluorescein Angiography in Proliferative Diabetic Retinopathy (RECOVERY Study): Report 1 |
| Q38792697 | Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial |
| Q41560304 | Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials |
| Q33518322 | Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation |
| Q33528327 | Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema |
| Q90720148 | Faster Sensitivity Loss around Dense Scotomas than for Overall Macular Sensitivity in Stargardt Disease: ProgStar Report No. 14 |
| Q33980785 | Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. |
| Q97593586 | Fractal analysis of retinal vasculature in normal subjects on ultra-wide field fluorescein angiography |
| Q94456649 | Hyperreflective Stress Lines and Macular Holes |
| Q38409630 | Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion: SCORE Study Report 15. |
| Q34444726 | Interventions for toxoplasma retinochoroiditis: a report by the American Academy of Ophthalmology |
| Q90201605 | Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial |
| Q35818988 | Intravitreal injection of triamcinolone: an emerging treatment for diabetic macular edema |
| Q41093061 | Intravitreal triamcinolone for management of idiopathic juxtafoveolar telangiectasis |
| Q45012496 | Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion |
| Q44127718 | Intravitreous triamcinolone acetonide as treatment for macular edema from central retinal vein occlusion. |
| Q46433069 | It's time for a clinical trial to investigate intravitreal triamcinolone for macular edema due to retinal vein occlusion: the SCORE study |
| Q88627052 | LONG-TERM PHYSICAL STABILITY, STERILITY, AND ANTI-VEGF BIOACTIVITY OF REPACKAGED BEVACIZUMAB IN 2-ML GLASS VIALS |
| Q48180775 | Localized retinal manifestations of paraneoplastic autoimmune retinopathy |
| Q34410765 | Long-term effects of ranibizumab on diabetic retinopathy severity and progression |
| Q45972929 | Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. |
| Q95940524 | Longitudinal Microperimetric Changes of Macular Sensitivity in Stargardt Disease After 12 Months: ProgStar Report No. 13 |
| Q98630680 | Longitudinal panretinal microaneurysm dynamics on ultra-widefield fluorescein angiography in eyes treated with intravitreal aflibercept for proliferative diabetic retinopathy in the recovery study |
| Q35563017 | Macular hole: improved understanding of pathogenesis, staging, and management based on optical coherence tomography |
| Q57293647 | Macular spatial distribution of preserved autofluorescence in patients with choroideremia |
| Q46760570 | Measurement and Reproducibility of Preserved Ellipsoid Zone Area and Preserved Retinal Pigment Epithelium Area in Eyes With Choroideremia. |
| Q91291389 | Microperimetry for geographic atrophy secondary to age-related macular degeneration |
| Q90776228 | Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study |
| Q90629960 | Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial |
| Q99400674 | Non-neovascular age-related macular degeneration with subretinal fluid |
| Q33265781 | Optical coherence tomography findings in central retinal artery occlusion. |
| Q92560202 | Patient-Reported Visual Function Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis of a Randomized Clinical Trial |
| Q33223098 | Preferential Hyperacuity Perimeter (PreView PHP) for detecting choroidal neovascularization study |
| Q33521026 | Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema |
| Q92336853 | Progression of Stargardt Disease as Determined by Fundus Autofluorescence Over a 12-Month Period: ProgStar Report No. 11 |
| Q47179460 | Propranolol for Proliferative Diabetic Retinopathy |
| Q46443141 | QUANTIFICATION OF INTRARETINAL HARD EXUDATES IN EYES WITH DIABETIC RETINOPATHY BY OPTICAL COHERENCE TOMOGRAPHY. |
| Q90342210 | Quantity of Intraretinal Hyperreflective Foci in Patients With Intermediate Age-Related Macular Degeneration Correlates With 1-Year Progression |
| Q95925318 | Relationship Between Nerve Fiber Layer Hemorrhages and Outcomes in Central Retinal Vein Occlusion |
| Q93028489 | Relationship Between Retinal Fractal Dimension and Nonperfusion in Diabetic Retinopathy on Ultrawide-Field Fluorescein Angiography |
| Q95523275 | Reply |
| Q54259683 | Reply: To PMID 24999721. |
| Q64970927 | Reproducibility of Measurements of Retinal Structural Parameters Using Optical Coherence Tomography in Stargardt Disease. |
| Q38226842 | Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab |
| Q35258971 | Response to aflibercept in patients with persistent exudation despite prior treatment with bevacizumab or ranibizumab for age-related macular degeneration |
| Q33390923 | Retinal detachment due to an outer retinal tear following laser prophylaxis for retinoschisis |
| Q37186423 | SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type |
| Q37427372 | SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design |
| Q35025786 | SCORE Study Report 8: Closed Tests for All Pair-Wise Comparisons of Means |
| Q35085700 | SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion |
| Q33402708 | SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion |
| Q33484531 | SCORE Study report 3: study design and baseline characteristics |
| Q98629655 | SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes with Central or Hemiretinal Vein Occlusion Managed with Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials |
| Q38838510 | SCORE2 Report 1: Techniques to Optimize Recruitment in Phase III Clinical Trials of Patients With Central Retinal Vein Occlusion |
| Q46169738 | SCORE2 Report 2: Study Design and Baseline Characteristics |
| Q46777540 | SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion |
| Q92251162 | SEVERITY OF DIABETIC MACULAR EDEMA CORRELATES WITH RETINAL VASCULAR BED AREA ON ULTRA-WIDE FIELD FLUORESCEIN ANGIOGRAPHY: DAVE Study |
| Q38042851 | Score Study Report 12: Development of venous collaterals in the Score Study |
| Q89236749 | Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease (SMART) Study: Design and Baseline Characteristics (Report No. 1) |
| Q33684191 | Small-gauge pars plana vitrectomy: a report by the American Academy of Ophthalmology |
| Q104611767 | Spectral Domain Optical Coherence Tomography Predictors of Visual Acuity in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) |
| Q73453503 | Spontaneous resolution of vitreomacular traction documented by optical coherence tomography |
| Q34245848 | Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study System for Evaluation of Stereoscopic Color Fundus Photographs and Fluorescein Angiograms |
| Q47555884 | Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial |
| Q44715598 | Subluxated/dislocated lens and hyphema as features of retinoblastoma |
| Q38747210 | The Clinical Importance of Changes in Diabetic Retinopathy Severity Score |
| Q95293104 | The Effect of Attention on Fixation Stability during Dynamic Fixation Testing in Stargardt Disease |
| Q30878832 | The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study system for evaluation of optical coherence tomograms: SCORE study report 4. |
| Q36120654 | The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials |
| Q33416368 | Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema |
| Q33903278 | Transpupillary thermotherapy |
| Q30790468 | Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration |
| Q57812624 | Treatment of Central Retinal Vein Occlusion-A New Look at a Blast From the Past |
| Q35563022 | Treatment of central retinal vein occlusion with triamcinolone acetonide: an optical coherence tomography study. |
| Q79865149 | Two discrete uveal melanomas in a child with ocular melanocytosis |
| Q89414151 | Ultra-Wide-Field Fluorescein Angiography-Guided Normalization of Ischemic Index Calculation in Eyes With Retinal Vein Occlusion |
| Q91703327 | Ultra-Widefield Fundus Autofluorescence Imaging of Patients with Retinitis Pigmentosa: A Standardized Grading System in Different Genotypes |
| Q101138932 | Visual Acuity in Retinal Vein Occlusion-, Diabetic-, and Uveitic Macular Edema: Central Subfield Thickness and Ellipsoid Zone Analysis |
| Q36257726 | β2-Adrenergic Receptor Antagonism Attenuates CNV Through Inhibition of VEGF and IL-6 Expression |
Search more.